Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Instagram Outage Disrupts Thousands of U.S. Users 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
NEW YORK, March 21, 2016 -- Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Migralex™, a commercially available over-the-counter medication for treating pain.
As part of the transaction, all assets from Migralex, Inc. will be transferred to Ember Therapeutics, Inc.
“This is our second acquisition this quarter. The addition of a great brand, such as Migralex™, to our pipeline will allow us to provide relief to over 150 million Americans suffering from recurrent pain,” said Joseph Hernandez, Executive Chairman of Ember Therapeutics, Inc. “Furthermore, as Migralex™ is a commercial stage asset, the revenue generated by this product will help further the development of our two Phase 3 ready clinical programs in osteoarthritis and regenerative medicine.”
As a result of over 25 years of research, world renowned neurologist, leading pain expert and founder of the New York Headache Center, Dr. Alexander Mauskop has developed and patented a breakthrough headache medicine that has been clinically proven to be highly effective in relieving most types of pain, including arthritis pain, tension headaches, sinus headaches, stress headaches, menstrual headaches, and various other pains. Dr. Mauskop’s Migralex™ is a patented product and is the strongest combination pain medicine available without a prescription. Its special rapid release formula gives fast acting relief, and is gentle on the stomach. Migralex™ reduces side effects common with other OTC pain relievers. It contains no caffeine, sodium or preservatives, and contains magnesium as a buffering agent.
Migralex™ is currently available at CVS, local pharmacies, and online at Amazon.com and the product website www.migralex.com. To learn more about Migralex™ please access www.migralex.com.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a pharmaceutical company developing targeted therapies for pain, osteoarthritis, kidney fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has a commercial stage pain product and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.
The Ruth Group Lee Roth (investors) (646) 536-7012 [email protected]
